STOCK TITAN

Genetic Technologies Ltd. - GENE STOCK NEWS

Welcome to our dedicated news page for Genetic Technologies Ltd. (Ticker: GENE), a resource for investors and traders seeking the latest updates and insights on Genetic Technologies Ltd..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Genetic Technologies Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Genetic Technologies Ltd.'s position in the market.

Rhea-AI Summary
Genetic Technologies (GENE) announces its commitment to innovation through strong global academic partnerships, continuous enhancement of geneType portfolio, and expansion of risk assessment tests. Collaborations with high-profile universities, ongoing research projects, and development of new tests demonstrate GTG's dedication to improving patient care and personalized medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.86%
Tags
none
-
Rhea-AI Summary
Genetic Technologies (GENE) announces the development of a groundbreaking risk assessment test for serious diseases, incorporating over 200 high penetrant genes to identify nearly 100% of people at risk. The test covers common cancers, cardiovascular disease, and type 2 diabetes, going beyond family history to identify patients at risk of disease. This innovation aims to revolutionize personalized preventative healthcare, providing physicians and patients with unparalleled insight into individual risk profiles.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.12%
Tags
none
-
Rhea-AI Summary
Genetic Technologies Limited (NASDAQ: GENE) announces the launch of a digital advertising campaign in the U.S. to drive Consumer Initiated Testing for geneType Risk Assessment Tests. The U.S. wellness testing market is projected to grow significantly, presenting a lucrative opportunity for GTG to tap into. Dr. Malcolm Bohm, a seasoned strategic advisor, will lead the initiative, leveraging his expertise in customer marketing and disruptive technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.55%
Tags
none
Rhea-AI Summary
Genetic Technologies Limited (NASDAQ: GENE) has released a business update for the quarter ending 31 December 2023, showcasing its pioneering initiatives in genomics-based tests for precision medicine. The company reported cash receipts totaling A$3.6m, including A$1.85m from customers and A$1.75 million from R&D Tax Incentive. Genetic Technologies also announced the appointment of 2 experienced commercial advisors to accelerate its Direct to Consumer plans for Genetype in the U.S. The company processed a record number of geneType tests and launched the Hereditary Breast & Ovarian Cancer Risk Assessment Test (HBOC) in the U.S. It also commenced a Precision Medicine Pilot with the Gold Coast Private Hospital and is expanding its global footprint in South East Asia and the UK. Genetic Technologies has also initiated activities associated with the CASSOWARY Trial, named as the sole industry partner for the $2.4 million clinical trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
none
-
Rhea-AI Summary
Genetic Technologies Limited (NASDAQ: GENE) has regained compliance with the minimum bid price requirement set forth by Nasdaq, maintaining a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, as announced on January 05, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
none
-
Rhea-AI Summary
RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, December 30, at 7 p.m. Eastern Time (ET). Genetic Technologies is executing a B2B commercialization strategy for its flagship geneType multi-risk test covering various diseases, with a global market expected to reach $4.6 billion by 2025. BioVie is a clinical-stage company developing transformative therapies for Alzheimer's, Parkinson's, and liver diseases, with positive trending data from a Phase 3 trial in AD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
none
Rhea-AI Summary
RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, December 30, at 7 p.m. Eastern Time (ET). Genetic Technologies is executing a B2B commercialization strategy for its flagship geneType multi-risk test covering various diseases, with a global market expected to reach $4.6 billion by 2025. BioVie is a clinical-stage company developing transformative therapies for Alzheimer's, Parkinson's, and liver diseases, with positive trending data from a Phase 3 trial in AD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
none
-
Rhea-AI Summary
Genetic Technologies (GTG) has recently announced transformative initiatives, including a partnership with Gold Coast Private Hospital for a 50-patient pilot study, a world-first risk assessment test for Melanoma, and a groundbreaking partnership with the University of Melbourne. These initiatives mark a significant leap forward in precision medicine and early disease detection, positioning geneType at the forefront of transforming DNA testing into a cost-effective, efficient tool for personalized cancer risk management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.45%
Tags
none
-
Rhea-AI Summary
Genetic Technologies Limited (GTG) announces a share consolidation of its ordinary shares and a change of ratio in its American Depositary Share program. The Effective Date is expected to be December 14, 2023. The Shares will continue to be traded on the ASX under the symbol “GTGDA”, from 14 December to 22 December 2023, before reverting to the symbol “GTG” from 27 December 2023. The ADSs will continue to be traded on The Nasdaq Stock Exchange under the symbol “GENE”.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.61%
Tags
none
Rhea-AI Summary
Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE) provides an update on its activities for the quarter ending September 30, 2023. Highlights include a partnership with Gold Coast Private Hospital, geneType Multi-Test approval for Pancreatic Cancer, Melanoma, and Atrial Fibrillation in Australia, and being named the sole industry partner for a Medical Research Future Fund (MRFF) grant. Receipts from customers were A$2.0 million, and a peer-reviewed research paper validated geneType's Pancreatic Cancer risk test.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.47%
Tags
partnership clinical trial
Genetic Technologies Ltd.

Nasdaq:GENE

GENE Rankings

GENE Stock Data

11.12M
101.76M
0.64%
0.72%
Testing Laboratories
Professional, Scientific, and Technical Services
Link
Australia
Melbourne

About GENE

genetic technologies (asx: gtg, nasdaq global market: gene) is leading-edge genetic testing and reproductive services business which, together with an extensive range of international patents and allied research activities, aims at uncovering the impact of dna on health. throughout the asia pacific region, we translate specialised genetic tests into products and services that optimise the health knowledge and outcomes in humans, animals and plants.